Edwards Lifesciences Corporation $EW Shares Bought by Bank of Montreal Can

Bank of Montreal Can lifted its position in Edwards Lifesciences Corporation (NYSE:EW) by 23.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 844,155 shares of the medical research company’s stock after buying an additional 159,257 shares during the period. Bank of Montreal Can owned approximately 0.15% of Edwards Lifesciences worth $65,650,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of EW. Vanguard Group Inc. boosted its position in shares of Edwards Lifesciences by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 70,363,210 shares of the medical research company’s stock valued at $5,472,147,000 after purchasing an additional 365,581 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Edwards Lifesciences by 8.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 19,010,227 shares of the medical research company’s stock worth $1,478,425,000 after purchasing an additional 1,423,365 shares in the last quarter. Jennison Associates LLC lifted its stake in Edwards Lifesciences by 19.6% during the third quarter. Jennison Associates LLC now owns 13,958,774 shares of the medical research company’s stock valued at $1,085,574,000 after purchasing an additional 2,287,783 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Edwards Lifesciences by 0.4% during the second quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock worth $990,074,000 after buying an additional 45,555 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in Edwards Lifesciences by 111.2% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after buying an additional 4,805,819 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 24,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $83.84, for a total value of $2,012,160.00. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the transaction, the chief financial officer directly owned 39,699 shares in the company, valued at $3,371,239.08. The trade was a 24.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,718 shares of company stock valued at $5,236,281 in the last three months. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Down 0.6%

NYSE:EW opened at $84.62 on Friday. The stock has a market cap of $49.15 billion, a PE ratio of 46.24, a price-to-earnings-growth ratio of 2.22 and a beta of 0.93. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.89. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. The stock’s 50-day moving average is $82.48 and its two-hundred day moving average is $81.57.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The company had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a net margin of 17.69% and a return on equity of 14.50%. The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on EW shares. Barclays restated an “overweight” rating and issued a $104.00 target price (up from $103.00) on shares of Edwards Lifesciences in a report on Monday, January 12th. Piper Sandler reiterated an “overweight” rating and issued a $100.00 price target (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. BTIG Research reaffirmed a “buy” rating and set a $103.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Finally, Truist Financial set a $89.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.